Advancing Rationally Designed Antibody Leads into Development Candidates Through Structural Validation & Translational Characterisation
12:30 pm - Wednesday 13th January 2027
- Leverage phage display, structural biology and Cryo-EM to identify, characterise and down-select antibody leads against novel pan-cancer target onco-fetal chondroitin sulfate
- Integrate target biology, binding characterisation and in vivo localisation studies to prioritise candidates with the greatest translational potential
- Optimise pharmacokinetic profile using structural biology and functional datasets to de-risk candidate selection and increase confidence in progression toward clinical development
